Skip to main content
Veterinary Medicines

Numelvi 31.6 mg - Tablet

Authorised
  • Atinvicitinib

Product identification

Medicine name:
Numelvi 31.6 mg - Tablet
Active substance:
  • Atinvicitinib
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Atinvicitinib
    Presentation_strength:31.6 mg Reference:Hse Index:0
Pharmaceutical form:
This information is not available for this product.
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QD11AH93
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Polyethylene bottle, Package_size:Polyethylene bottle containing 90 tablets
  • Packaging:Cardboard box, Package_size:Cardboard box containing 1 blister strip with 30 tablets
  • Packaging:Cardboard box, Package_size:Cardboard box containing 3 blisters (30 each) contain 90 tablets in total
  • Packaging:Polyethylene bottle, Package_size:Polyethylene bottle containing 30 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet Ges.m.b.H.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 30/07/2025
Download
Bulgarian (PDF)
Published on: 30/07/2025
Croatian (PDF)
Published on: 30/07/2025
Czech (PDF)
Published on: 30/07/2025
Danish (PDF)
Published on: 30/07/2025
Dutch (PDF)
Published on: 30/07/2025
Estonian (PDF)
Published on: 30/07/2025
Finnish (PDF)
Published on: 30/07/2025
French (PDF)
Published on: 30/07/2025
German (PDF)
Published on: 30/07/2025
Greek (PDF)
Published on: 30/07/2025
Hungarian (PDF)
Published on: 30/07/2025
Icelandic (PDF)
Published on: 30/07/2025
Italian (PDF)
Published on: 30/07/2025
Latvian (PDF)
Published on: 30/07/2025
Lithuanian (PDF)
Published on: 30/07/2025
Maltese (PDF)
Published on: 30/07/2025
Norwegian (PDF)
Published on: 30/07/2025
Polish (PDF)
Published on: 30/07/2025
Portuguese (PDF)
Published on: 30/07/2025
Romanian (PDF)
Published on: 30/07/2025
Slovak (PDF)
Published on: 30/07/2025
Slovenian (PDF)
Published on: 30/07/2025
Spanish (PDF)
Published on: 30/07/2025
Swedish (PDF)
Published on: 30/07/2025
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."